Abstract: Provided herein are oral liquid formulations of hydrocortisone. Also provided herein are methods of making and using hydrocortisone oral liquid compositions for the treatment of certain diseases including endocrine disorders, rheumatic disorders, collagen diseases, dermatologic diseases, and others.

Abstract: 1?-Cyano nucleoside analogs of Formula I and methods of using said compounds, singly or in combination with additional agents, and salts or pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.

Abstract: Method and composition for treating or preventing a respiratory illness. The method includes administering at least one dose of a pharmaceutically acceptable fluid having a pH less than 3.0 into contact with at least one region of the respiratory tract present in a patient in need thereof. Respiratory illness that can be treated include COVID-19.

Abstract: The invention features formulations for the local delivery of therapeutically effective doses of curcumin to treat head and neck disorders and upper aerodigestive disorders. Also disclosed are use of the formulations for delivery of other phytochemicals, or the combination of phytochemicals for the treatment of said disorders. Furthermore, these formulations can be used to deliver the recommended daily allowance of vitamins and/or minerals to children or adults.

Abstract: A method for decreasing the incidence rate and/or recurrent rate of cancer is provided. The method comprises administering to a subject in need an effective amount of butylidenephthalide (BP).

Abstract: Andrographolide 240 mg/day orally is the first treatment shown to significantly benefit progressive forms of Multiple Sclerosis in human patients.

Abstract: An isolated or synthesized compound of Formula I and salts thereof are provided. A compound isolated from Actinomadura and having a chemical formula of C38H60O12 is also provided. Compositions including the compounds and methods of using the compounds to treat bacterial infections including gram positive infections such as C. difficile are also disclosed.

Abstract: The present invention relates to a pharmaceutical composition including (i) as a major ingredient, a novel 5-{4-(Aminosulfonyl)phenyl}-2,2-dimethyl-4-(3-fluorophenyl)-3(2H)-furanone compound (Formula 1) or a pharmaceutically acceptable salt thereof, which has a crystalline form A or G, or a mixed form thereof and has a 50% volume particle diameter (d(0.5)) of 3 ?m to 9 ?m and a 90% volume particle diameter (d(0.9)) of 10 ?m to 50 ?m, (ii) a pharmaceutically acceptable diluent, and (iii) a pharmaceutically acceptable lubricant. The pharmaceutical composition of the present invention has the advantages of good stability, high dissolution rate, improved content uniformity, and excellent pharmacokinetic properties. Due to these advantages, as a non-steroidal anti-inflammatory drug, the pharmaceutical composition of the present invention may be effective in treating inflammation or pain.

Abstract: The present invention provides A PPAR? activator comprising a butenolide compound represented by the formula (1) or a pharmaceutically acceptable salt thereof: wherein R1 represents a hydrogen atom, a phosphate group, a fatty acid group, an alkyl group having 1 to 4 carbon atoms and optionally having a substituent or a sugar residue optionally having a substituent, and R2 represents a phenyl group, a methylphenyl group, a dimethylphenyl group, an ethylphenyl group, a benzyl group, a methylbenzyl group, a dimethylbenzyl group, an ethylbenzyl group, a phenethyl group, a methylphenethyl group, a dimethylphenethyl group, or an ethylphenethyl group.

Abstract: The purpose of the present invention is to provide an anticancer agent for potentiating an antitumor effect, alleviating side effects, and further extending the survival rate by concomitant use with a component having an anticancer effect. An anticancer agent combining arctigenin and a component other than arctigenin that has an anticancer effect, in which the anticancer agent may be a combination drug or may be a kit configured from a formulation containing arctigenin and a formulation containing a component that has an anticancer effect, and the concomitant use of arctigenin and the component having an anticancer effect more strongly inhibits tumor growth and reduces the proportion of cancer stem cells in the tumor, making it possible to extend the total survival time and to alleviate side effects caused by the component having an anticancer effect.

Abstract: The present invention is intended to provide a novel anticancer agent which is effective to a cancer. After administering an agent prepared using burdock fruit extract to a pancreas cancer patient so that a dose of arctigenin was 100 mg or more per day, the tumor reducing effect was observed, and, in addition, lowering of tumor markers was confirmed. The present invention provides an anticancer agent containing arctigenin, wherein a dose of the arctigenin is 100 mg or more per day. In addition, the present invention provides the anticancer agent containing arctigenin and arctiin at a weight ratio of arctigenin/arctiin=0.7 to 1.3.

Abstract: Provided herein is a method for preventing or treating neurodegenerative disease in a subject, comprising administrating to the subject an effective amount of a composition which comprises a semen biotae extract. The neurodegenerative disease is associated with ?-synuclein, such as Alzheimer's disease, Parkinson's disease, Huntington disease, or Amyotrophic lateral sclerosis.

Abstract: Compositions containing one or more COX inhibitors in combination with one or more antagonists of 20-HETE (20-hydroxyeicosatetraeonic acid), and optionally a pharmaceutically acceptable excipient are provided. Preferred compositions include rofecoxib in combination with HET0016. The compositions have reduced side effects due to COX inhibitors. Methods for treating or inhibiting cancer using the disclosed compositions are also provided.

Abstract: An ascorbic acid derivative composition of a first aspect according to the present invention consists of a salt of a compound (1) represented by a general formula (1) shown below; and a salt of a compound (2) represented by a general formula (2) shown below, wherein a ratio of the salt of the compound (2) with respect to a total amount of the salt of the compound (1) and the salt of the compound (2) is from 0.1 to 10% by mass, wherein R1 represents a linear or branched alkyl group of 6 to 20 carbon atoms, R2 represents a linear or branched alkyl group of 6 to 20 carbon atoms, and R1 and R2 are the same or are different from each other.

Abstract: An agent for reducing graphene oxide and a method for preparing reduced graphene oxide or graphene are provided. An agent for reducing graphene oxide include a mixture of a reducing agent containing a halogen element with trifluoroacetic acid (CF3COOH).

Abstract: The present invention relates to compositions comprising Andrographis paniculata extracts combined with Ginkgo biloba extracts complexed with phospholipids. Moreover, the compositions administered in oils rich in ?-3 polyunsaturated fatty acids demonstrate a further synergic effect between the ingredients. Said compositions are useful in the treatment of neurodegenerative disorders, in particular Alzheimer's disease and multiple sclerosis.

Abstract: The invention provides novel phenylglyoxylic acid derivatives, which may be useful as intermediates for preparing stereoisomerically enriched drug compounds. The invention also provides methods of making phenylglyoxylic acid derivatives, and uses of phenylglyoxylic acid derivatives.

Abstract: The present invention relates to process for the preparation of fosamprenavir calcium.

Abstract: The invention provides novel compositions based on a structure designated as “Honaucin A”, including Honaucin A variants and analogs, and pharmaceutical compositions, liposomes and nanoparticles comprising them, and methods of making and using them. In one embodiment, these Honaucin A compounds, and variants and analogs thereof are used to ameliorate (including to treat or prevent) inflammation. In one embodiment, these Honaucin A compounds, and variants and analogs thereof are used to ameliorate (including to treat or prevent) inflammation. In one embodiment, these Honaucin A compounds, and variants and analogs thereof are used as bacterial quorumsensing inhibitors. Accordingly, in alternative embodiments the compositions of the invention are used as anti-bacterial agents.

Abstract: The effectiveness of interferon for treating multiple sclerosis and other demyelinating diseases is synergistically potentiated by concomitant administration of a compound of Formula (I): wherein R1 is H, alkyl or OH, R2 is hydroxyalkyl or alkyl-O-L1, R3 is H or OH, X is C(?CH2), CH(OH), or spirooxirane-2, Z is CH2CH(OH) or C(=0), and R4 is an optionally substituted L2-alkyl or L2-alkenyl, wherein L2 is an optionally substituted 3-furanyl or 3-fur-3-enyl moiety.

Abstract: Uses of a compound of any of Formulas I-VI as a cytotoxic inhibitor of undifferentiated cells are disclosed herein, as well as pharmaceutical compositions comprising a compound of any of Formulas I-VI, and methods for identifying a lead candidate for inhibiting undifferentiated cells. Further disclosed are uses of an SCD-1 inhibitor as a cytotoxic inhibitor of undifferentiated cells.

Abstract: Control or repellency of mosquitoes is accomplished by bringing the insects into contact with at least one of the compounds of the structure (I) wherein R is selected from —OH, ?O, —OC(O)R4, —OR6, —(OR6)2, wherein each R6 is independently selected from an alkyl group containing from 1 to 4 carbon atoms and R4 is a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero to two double bonds and from 1 to 15 carbon atoms; X is O or CH2, with the proviso that when X is O R can only be ?O; each Z is independently selected from (CH) and (CH2); y is a numeral selected from 1 and 2; R1 is selected from H or a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero to two double bonds and from 1 to 15 carbon atoms; R2 is selected from H and a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero to three double bonds and from 1 to 15 carbon atoms; R3 is selected from the group consisting of H and a branched or straight chain, satur

Abstract: Control or repellency of biting arthropods, particularly biting insects, is accomplished by bringing the biting arthropods into contact with combinations of compounds identical or related to those found on human/animal skin or in plants acting synergistically with one another, or in combination with conventional repellents like DEET®, para-menthane-3,8-diol (PMD), sec-butyl-2-(2-hydroxyethyl) piperidine carboxylate (“Picaridin”), or other nitrogen containing repellents selected from amines, amides and nitrogen containing heterocyclic compounds, or any synergistic combination of DEET®, PMD, Picaridin, or other nitrogen containing repellents selected from amines, amides and nitrogen containing heterocyclic compounds.

Abstract: Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, and in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. Antiviral activity of enzyme inhibitors is demonstrated.

Abstract: The present invention discloses a 4-((substituted phenyl)difluoromethyl)phenoxycarboxylic acid derivative and preparation process and use thereof. More specifically, the present invention relates to a compound of the following formula I, which is defined in the specification. The compounds according to the present invention can be used as PPAR agonists, and demonstrates a strong effect on reducing the levels of total cholesterol (TC), triglyceride (TG), and low density lipoprotein cholesterol (LDL-C) in blood plasma, and thus the compound according to the present invention can be used in the preparation of a medicament for treating or preventing hyperlipoidemia or cardio-cerebrovascular diseases caused by hyperlipoidemia, such as diabetes, atherosclerosis, stroke, coronary heart disease, etc. The present invention also relates to a novel intermediate compound for the preparation of the compound of formula I and preparation method thereof.

Abstract: Provided is a method for treating brain cancer or reducing temozolomide-resistance of brain cancer cells in a subject, comprising administrating to the subject an effective amount of an active ingredient selected from the group consisting of (Z)-butylidenephthalide of formula (I), a pharmaceutically acceptable salt of (Z)-butylidenephthalide, a pharmaceutically acceptable ester of (Z)-butylidenephthalide, and combinations thereof:

Abstract: The present invention relates to novel uses of compounds from Antrodia cinnamomea mycelia and mixtures comprising the compounds. The novel uses comprise whitening skin, combating skin ageing, reducing scar formation, inducing or enhancing liver regeneration, or treating fibrosis or a fibrosis-associated disorder in a subject in need thereof. The compounds have the formula and preferably are selected from 3-isobutyl-4-[4-(3-methyl-2-butenyloxy)phenyl]furan-2,5-dione, 3-isobutyl-4-[4-(3-methyl-2-butenyloxy)phenyl]-1H-pyrrol-2,5-dione, 3-isobutyl-4-[4-(3-methyl-2-butenyloxy)phenyl]-1H-pyrrol-1-ol-2,5-dione, 3R*,4S*-1-hydroxy-3-isobutyl-4-[4-(3-methyl-2-butenyloxy)phenyl]pyrrolidine-2,5-dione, and 3R*,4R*-1-hydroxy-3-isobutyl-4-[4-(3-methyl-2-butenyloxy)phenyl]pyrrolidine-2,5-dione.

Abstract: Compounds having formulas (I) to (VIII), salts thereof, or combinations thereof and pharmaceutical compositions comprising one or more these compounds are described herein for the treatment of HIV and neurodegenerative effects caused by HIV. Also provided herein are methods and a kit for inhibiting HIV-1, treating latent HIV in the brain, and preventing HIV-mediated cognitive decline and HIV dementia comprising administering the compounds having the formulas (I) to (VIII) and pharmaceutical compositions comprising the compounds having these formulas. The compounds having formulas I through VIII are curcumin analogs which are advantageously characterized as having anti-retroviral, neuroprotective, anti-glucosidase, and anti-HIV integrase properties. In one aspect, the pharmaceutical composition is delivered intranasally.

Abstract: The invention relates to the cosmetic use of a compound chosen from the compounds of formula (A) and the salts of same as an agent for depigmenting the skin and/or keratinous appendages.

Abstract: Provided in the present invention are various labdane diterpenoid compounds and derivatives thereof for use in preparation of a pharmaceutical composition for preventing or treating neurodegenerative diseases. Also provided in the present invention is a semen biotae extract comprising one or more labdane diterpenoid compounds and derivatives thereof for use in preparation of a pharmaceutical composition for preventing or treating neurodegenerative diseases.

Abstract: An arctigenin derivative used for anti-aging treatment, including protection of the skin from the sun and recovery of skin elasticity. A variety of fatty acid ester derivatives, alcohol ether derivatives and alkylated derivatives are used as the arctigenin derivatives. Agents for controlling ET-1 production, elastase inhibitors, and anti-inflammatory agents are prepared. Such arctigenin derivatives are particularly useful as an external agent for the skin, such as an anti-inflammatory external agent, a sunscreen external agent, or an external agent for recovering elasticity.

Abstract: There is provided compositions and methods for the treatment of respiratory conditions such as pulmonary hypertension and sickle-cell disease in a patient in need thereof. The composition and method are for treating a patient in need thereof by inhalation of a composition containing amino acid ester compounds comprising at least one nitric oxide releasing group and pharmaceutical salts thereof.

Abstract: Novel compounds of formula (I) their use as germination trap for parasitic weeds, for the regulation of branching, tillering and root development, for enhancement of cambium growth, for the regulation of hyphal growth of mycorrhizal fungi and compositions comprising compounds of formula (I) and insecticides and/or fungicides.

Abstract: The present invention relates to a new use of lignan-type compounds or an extract of nutmeg or aril of nutmeg comprising the same. More particularly, the present invention relates to a composition for skin whitening comprising a lignan-type compound or an extract of nutmeg or aril of nutmeg comprising the same. Because the lignan compound represented by Chemical Formulas 1 to 3 or the extract of nutmeg or aril of nutmeg has superior skin whitening activity by inhibiting melanin production and tyrosinase activity, it can be used for the preparation of a cosmetic composition, food composition or pharmaceutical composition for skin whitening.

Abstract: The present disclosure generally relates to therapeutic nanoparticles. Exemplary nanoparticles disclosed herein may include about 0.1 to about 40 weight percent of a therapeutic agent and about 10 to about 90 weight percent a diblock poly(lactic) acid-poly(ethylene)glycol copolymer or a diblock poly(lactic)-co-poly(glycolic) acid-poly(ethylene)glycol copolymer, wherein the diblock poly(lactic) acid-poly(ethylene)glycol copolymer comprises poly(lactic) acid having a number average molecule weight of about 30 kDa to about 90 kDa or the diblock poly(lactic)-co-poly(glycolic) acid-poly(ethylene)glycol copolymer comprises poly(lactic)-co-poly(glycolic) acid having a number average molecule weight of about 30 kDa to about 90 kDa.

Abstract: The invention is a method of exterminating a harmful insect with an agricultural and horticultural insecticide containing one or more kinds of compound (A) selected from a specific polyoxyethylene fatty acid ester, a specific polyoxyethylene sorbitan fatty acid ester, a specific (poly)glycerol fatty acid ester, and a specific alkyl saccharide, and a compound (B) of an alcohol having a linear or branched alkyl group having 8 to 14 carbon atoms or a linear or branched alkyl ether having 6 to 12 carbon atoms, provided that an agricultural chemical ingredient of an agricultural chemical is not substantially contained.

Abstract: Compounds are used as agents that deter feeding of crops by agricultural pests such as hemiptera, lepidoptera and coleoptera, including, but not limited to, stink bugs, codling moth larvae and granary weevils.

Abstract: Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient.

Abstract: The present invention relates to novel strigolactam derivatives of formula (I) to processes and intermediates for preparing them, to plant growth regulator compositions comprising them and to methods of using them for controlling the growth of plants and/or promoting the germination of seeds.

Abstract: The subject invention is directed to a pharmaceutical composition comprising an open matrix network carrying a pharmaceutically active ingredient, wherein the open matrix network comprises levan.

Abstract: Hydroxytyrosol or olive juice containing hydroxytyrosol in combination with at least one of the compounds selected from the group consisting of: creatine, coenzyme Q10, resveratrol, caffeine, carnitine, B vitamins (B1, B2, B3, B5, B6, and/or B12) and ginseng (preferably: root) extract. can be used to maintain or increase mitochondrial biogenesis in cardiac muscle, skeletal muscles, and liver tissue.

Abstract: Provided are compounds and compositions derived from Pseudomonas sp., particularly, Pseudomonas fluorescens or Pseudomonas protegens and more particularly strain having the identifying characteristics of Pseudomonas ATCC 55799 having antimicrobial properties and particularly, antibacterial properties.

Abstract: The present invention provides methods and compositions for treating leukemia by cyclohexenone compounds.

Abstract: This invention is directed to analogs of 5-(tetradecyloxy)-2-furancarboxylic acid (TOFA) and their use in the treatment of dermatological disorders or conditions characterized by sebaceous gland hyperactivity, such as acne and oily skin, and other dermatological disorders and conditions. This invention is also directed to pharmaceutical compositions comprising analogs of TOFA and a pharmaceutically acceptable excipient for dermatological or oral administration.

Abstract: A wet wipe includes a cleansing composition and a substrate. The cleansing composition includes a preservative enhancing agent selected from the group consisting of caprylyl glycol; caprylyl glyceryl ether; glyceryl caprylate; sorbitan caprylate; ethylhyexyl glycerin, and combinations thereof. The cleansing composition includes a preservative selected from the group consisting of benzoic acid; lactic acid; sorbic acid; malic acid; maleic acid, and combinations thereof. The cleansing composition has a pH less than about 4. A method of making the cleansing composition may include dissolving one or more preservatives with water to form a solution; adding a rheology modifier to the solution; adding an emulsifier to the solution; adding a preservative enhancing agent to the solution; and adding citric acid to the solution.

Abstract: The invention provides methods and compositions for the diagnosis, prognosis and treatment of respiratory tract diseases. Specifically, the invention provides diagnosis, prognosis and treatment of respiratory infections using bitter and sweet taste signal transduction pathways. In one aspect, the invention relates to a method for treating a respiratory infection by administering a composition to the respiratory tract of a subject in an amount capable of activating bitter taste signaling and/or inhibiting sweet taste signaling. The composition comprises at least a bitter receptor agonist and, optionally, a pharmaceutically acceptable carrier for delivering the composition to the respiratory tract. In another aspect, the invention relates to a composition for treatment of a respiratory infection. Such composition comprises at least a bitter receptor agonist and, optionally, a pharmaceutically acceptable carrier for delivering the composition to the respiratory tract.

Abstract: A method for inhibiting formation of adhesions following abdominal surgery which involves application of an anti-static fatty acid ethoxylated amide (Cocamide DEA) in a matrix that is placed in the peritoneal cavity at the conclusion of an abdominal surgery and which releases this anti-adhesive chemical over a predetermined time in a range up to seven days. Tests conducted on laboratory rats established that the method reduced the incidence of adhesions from 100 percent (100%) in a test model to near zero in the majority of treated animals. In an alternative embodiment, andrographalide was delivered via a pump with similar results. In still another embodiment, an effective amount of 50% phosphatidylchorene and propylene glycol was delivered, via a pump, into the abdominal cavity, again with similar results.

Abstract: A method for treatment and or/prevention of dyslipidemia is provided. The invention relates to reducing low density lipoprotein cholesterol concentration by using naturally occurring diterpene (16?-hydroxycleroda-3,13(14)Z-dien-15,16-olide, a compound having formula (1)) isolated from leaves of Polyalthia longifolia.

Abstract: The present invention includes embodiments for treatment and/or prevention of sickle cell disease that employ Hydroxyfasudil or Isocoronarin D alone or either in conjunction with each other or an inducer of HbF production. The compounds may act synergistically, and the compounds employed circumvent the side effects seen with Hydroxyurea.

Abstract: The invention relates to novel compounds of the formula (I) in which W, X, Y, Z, and CKE have the meanings given above, to a plurality of processes and intermediates for their preparation and to their use as pesticides and/or herbicides and/or fungicides. Moreover, the invention relates to selectively herbicidal compositions comprising, firstly, the biphenyl-substituted cyclic ketoenols and, secondly, a crop plant compatibility-improving compound. The present invention furthermore relates to the boosting of the action of crop protection compositions comprising in particular biphenyl-substituted cyclic ketoenols through the addition of ammonium or phosphium salts and optionally penetrants, to the corresponding compositions, to processes for their preparation and to their use in crop protection as insecticides and/or nematicides and/or acaricides and/or fungicides and/or for preventing unwanted plant growth.